Skip To Main Content
Lauren Biscaldi on Muck Rack

Lauren Biscaldi

(She/Her)
New Jersey, New York
As seen in: The Michael J. Fox Foundation for Parkinson's Research, Psychiatric Times, The Clinical Advisor, American Journal of Managed Care, Monthly Prescribing Reference, Infection Control Today, Contemporary OB/GYN, Cancer Therapy Advisor, Psychiatry Advisor, Dermatology Times, Renal & Urology News and
Covers:  I cover all aspects of healthcare and life sciences, including pharmacy, primary care, oncology, dermatology, infectious diseases, and healthcare policy.
Lead editor @MichaelJFoxOrg. @NewhouseSU alum (G'20). Dog mom.

Get in touch with Lauren

Contact Lauren, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Articles

Liver Transplant Candidates with Alcohol-Associated Hepatitis More Likely to Reach Transplant Following Clinical Improvement

|
By Lauren Biscaldi
| Gastroenterology Advisor Verified
Liver transplant candidates with alcohol-associated hepatitis are more likely to reach liver transplant and less likely to be removed from the transplant list due to clinical improvement, according to research results presented at the American College of Gastroenterology 2026 Annual Scientific Meeting, held October 9 to 14, 2026, in Nashville, Tennessee.
Open in Who Shared Issue with article?

Efgartimod Maintains Safety Profile in Open-Label Extension Study

|
By Lauren Biscaldi
| Dermatology Advisor Verified
Efgartimod therapy is well-tolerated in adults with Sjögren disease, according to results of a poster presented at the 2026 Congress of Clinical Rheumatology West, held September 17 to 26 in Huntington Beach, California. Efgartimod is a human immunoglobulin G1 (IgG1) antibody Fc fragment engineered for increased affinity to the neonatal Fc receptor that selectively reduces IgG autoantibodies, potentially improving disease manifestations in Sjögren disease.
Open in Who Shared Issue with article?

Efgartimod Maintains Safety Profile in Open-Label Extension Study

|
By Lauren Biscaldi
| Rheumatology Advisor Verified
Efgartimod therapy is well-tolerated in adults with Sjögren disease, according to results of a poster presented at the 2026 Congress of Clinical Rheumatology West, held September 17 to 26 in Huntington Beach, California. Efgartimod is a human immunoglobulin G1 (IgG1) antibody Fc fragment engineered for increased affinity to the neonatal Fc receptor that selectively reduces IgG autoantibodies, potentially improving disease manifestations in Sjögren disease.
Open in Who Shared Issue with article?
See all 1,239 licensed articles (1,472 Total)